Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
Annals of the Academy of Medicine, Singapore
|
April 1, 2026
The APLC expert consensus recommendations on the management of chronic lymphocytic leukaemia in Asia
Shin Yeu Ong, Thomas Chan, Eric Wai Choi Tse, et al.
Internal Medicine Journal
|
December 26, 2023
Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignancies
Ashlea Campbell, Benjamin Teh, Stephen Mulligan, et al.
Internal Medicine Journal
|
July 7, 2026
Australasian chronic lymphocytic leukaemia consensus statement: 2026 update
Sean McKeague, Joanna Katarzyna Czerwinski, Xavier Badoux, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 26, 2018
Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Jacqueline C Barrientos, Susan O'Brien, Jennifer R Brown, et al.
Cytometry. Part B, Clinical Cytometry
|
October 13, 2017
Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project
Andy C Rawstron, Karl-Anton Kreuzer, Asha Soosapilla, et al.
Internal Medicine Journal
|
May 17, 2020
Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic
Pietro Di Ciaccio, Georgia McCaughan, Judith Trotman, et al.
Blood Advances
|
December 7, 2020
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial
Meletios Dimopoulos, Ramon Garcia Sanz, Hui-Peng Lee, et al.
Internal Medicine Journal
|
May 28, 2021
COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement
Georgia McCaughan, Pietro Di Ciaccio, Michelle Ananda-Rajah, et al.
Blood
|
July 31, 2020
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study
Constantine S Tam, Stephen Opat, Shirley D'Sa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 21, 2023
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study
Meletios A Dimopoulos, Stephen Opat, Shirley D'Sa, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
Annals of the Academy of Medicine, Singapore
|
April 1, 2026
The APLC expert consensus recommendations on the management of chronic lymphocytic leukaemia in Asia
Shin Yeu Ong, Thomas Chan, Eric Wai Choi Tse, et al.
Internal Medicine Journal
|
December 26, 2023
Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignancies
Ashlea Campbell, Benjamin Teh, Stephen Mulligan, et al.
Internal Medicine Journal
|
July 7, 2026
Australasian chronic lymphocytic leukaemia consensus statement: 2026 update
Sean McKeague, Joanna Katarzyna Czerwinski, Xavier Badoux, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 26, 2018
Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Jacqueline C Barrientos, Susan O'Brien, Jennifer R Brown, et al.
Cytometry. Part B, Clinical Cytometry
|
October 13, 2017
Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project
Andy C Rawstron, Karl-Anton Kreuzer, Asha Soosapilla, et al.
Internal Medicine Journal
|
May 17, 2020
Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic
Pietro Di Ciaccio, Georgia McCaughan, Judith Trotman, et al.
Blood Advances
|
December 7, 2020
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial
Meletios Dimopoulos, Ramon Garcia Sanz, Hui-Peng Lee, et al.
Internal Medicine Journal
|
May 28, 2021
COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement
Georgia McCaughan, Pietro Di Ciaccio, Michelle Ananda-Rajah, et al.
Blood
|
July 31, 2020
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study
Constantine S Tam, Stephen Opat, Shirley D'Sa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 21, 2023
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study
Meletios A Dimopoulos, Stephen Opat, Shirley D'Sa, et al.
Page
of 3